• Publications
  • Influence
Randomized, double‐blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
TLDR
The results of two double-blind studies evaluating the efficacy and safety of eflornithine HCl 13.9% cream in women with unwanted facial hair are reported. Expand
Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair.
TLDR
The results demonstrate that eflornithine HCl 13.9% cream does not have contact sensitising, photocontact allergic or phototoxic properties, and has a favourable dermal safety profile appropriate for a topical treatment to be applied routinely. Expand
The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism *
TLDR
Eflornithine is an effective treatment for unwanted facial hair in women, as reported by the patients, and ESTEEM addresses the specific concerns of women with hirsutism. Expand
The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris
TLDR
This randomized 10–week study compared the efficacy of benzoyl peroxide 5%/erythromycin 3% gel with erystromycin 4%/zinc 1.2% solution in 72 acne vulgaris patients to find the most effective treatment. Expand
A promising new treatment for solar lentigines.
TLDR
When used with sunscreen of SPF 25 or greater, 4HA/tretinoin was safe and well tolerated and did not produce any unexpected or unusual adverse events. Expand
Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair
TLDR
The results demonstrate that eflornithine HCl 13.9% cream does not have contact sensitising, photocontact allergic or phototoxic properties, and has a favourable dermal safety profile appropriate for a topical treatment to be applied routinely. Expand